Free Trial
NYSE:ZBH

Zimmer Biomet (ZBH) Stock Price, News & Analysis

Zimmer Biomet logo
$105.58 +0.83 (+0.79%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$105.70 +0.11 (+0.10%)
As of 09/5/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zimmer Biomet Stock (NYSE:ZBH)

Key Stats

Today's Range
$104.49
$106.20
50-Day Range
$90.63
$107.64
52-Week Range
$89.22
$114.72
Volume
1.17 million shs
Average Volume
1.29 million shs
Market Capitalization
$20.92 billion
P/E Ratio
25.69
Dividend Yield
0.91%
Price Target
$111.00
Consensus Rating
Hold

Company Overview

Zimmer Biomet Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

ZBH MarketRank™: 

Zimmer Biomet scored higher than 89% of companies evaluated by MarketBeat, and ranked 121st out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.37, and is based on 9 buy ratings, 8 hold ratings, and 2 sell ratings.

  • Upside/Downside

    The consensus price target for Zimmer Biomet is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Zimmer Biomet has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zimmer Biomet's stock forecast and price target.
  • Earnings Growth

    Earnings for Zimmer Biomet are expected to grow by 7.91% in the coming year, from $8.22 to $8.87 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zimmer Biomet is 25.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 278.13.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zimmer Biomet is 25.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.29.

  • Price to Earnings Growth Ratio

    Zimmer Biomet has a PEG Ratio of 2.08. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Zimmer Biomet has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zimmer Biomet's valuation and earnings.
  • Percentage of Shares Shorted

    3.52% of the float of Zimmer Biomet has been sold short.
  • Short Interest Ratio / Days to Cover

    Zimmer Biomet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Zimmer Biomet has recently increased by 17.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Zimmer Biomet has a dividend yield of 0.91%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Zimmer Biomet does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Zimmer Biomet is 23.36%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.82% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

  • Read more about Zimmer Biomet's dividend.
  • Percentage of Shares Shorted

    3.52% of the float of Zimmer Biomet has been sold short.
  • Short Interest Ratio / Days to Cover

    Zimmer Biomet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Zimmer Biomet has recently increased by 17.37%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Zimmer Biomet has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Zimmer Biomet this week, compared to 18 articles on an average week.
  • Search Interest

    Only 5 people have searched for ZBH on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,000.00 in company stock.

  • Percentage Held by Insiders

    Only 1.39% of the stock of Zimmer Biomet is held by insiders.

  • Percentage Held by Institutions

    88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zimmer Biomet's insider trading history.
Receive ZBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Stock News Headlines

Zimmer Biomet Issues CHF 600 Million Debt Securities
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Q3 EPS Estimates for Zimmer Biomet Raised by Zacks Research
Do Wall Street Analysts Like Zimmer Biomet Stock?
See More Headlines

ZBH Stock Analysis - Frequently Asked Questions

Zimmer Biomet's stock was trading at $105.63 at the beginning of the year. Since then, ZBH stock has decreased by 0.0% and is now trading at $105.5850.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) issued its earnings results on Thursday, August, 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company's revenue was up 7.0% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Zimmer Biomet: Respondwell, Clinical Graphics, CD Diagnostics, Medtech SAS, Compression Therapy Products, LDR Holding, Cayenne Medical, and others.

Zimmer Biomet's top institutional shareholders include Vanguard Group Inc. (11.74%), Dodge & Cox (11.15%), State Street Corp (4.42%) and American Century Companies Inc. (2.88%). Insiders that own company stock include Chad F Phipps, Sang Yi, Lori Winkler, Robert Hagemann, Michael W Michelson, Sreelakshmi Kolli and Betsy J Bernard.
View institutional ownership trends
.

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zimmer Biomet investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

Record date for 7/31 Dividend
6/26/2025
Ex-Dividend for 7/31 Dividend
6/26/2025
Dividend Payable
7/31/2025
Last Earnings
8/07/2025
Today
9/07/2025
Record date for 10/31 Dividend
9/30/2025
Ex-Dividend for 10/31 Dividend
9/30/2025
Next Earnings (Estimated)
10/29/2025
Dividend Payable
10/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:ZBH
Previous Symbol
NYSE:ZMH
CIK
1136869
Employees
17,000
Year Founded
1927

Price Target and Rating

High Price Target
$135.00
Low Price Target
$95.00
Potential Upside/Downside
+5.1%
Consensus Rating
Hold
Rating Score (0-4)
2.37
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
$4.11
Trailing P/E Ratio
25.69
Forward P/E Ratio
12.84
P/E Growth
2.08
Net Income
$903.70 million
Net Margins
10.51%
Pretax Margin
12.42%
Return on Equity
12.76%
Return on Assets
7.21%

Debt

Debt-to-Equity Ratio
0.54
Current Ratio
1.87
Quick Ratio
0.96

Sales & Book Value

Annual Sales
$7.68 billion
Price / Sales
2.72
Cash Flow
$13.18 per share
Price / Cash Flow
8.01
Book Value
$62.67 per share
Price / Book
1.68

Miscellaneous

Outstanding Shares
198,100,000
Free Float
195,342,000
Market Cap
$20.92 billion
Optionable
Optionable
Beta
0.68

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:ZBH) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners